Skip to main content

Table 2 Outcomes of kidney transplantation

From: Evaluation of the effect of high dose intravenous vitamin C on delayed allograft function in deceased donor kidney transplantation: a preliminary report

Outcome

Vitamin C arm (n = 9)

Placebo arm (n = 10)

P

Primary

 DGFa, dialysis criteria, n (%)

1 (11.1)

1 (10.0)

> 0.99

 DGFa, urine output criteria, n (%)

1 (11.1)

2 (20.0)

> 0.99

 DGFa, Scr trend criteria, n (%)

2 (22.2)

2 (20.0)

> 0.99

 DGF, any criteria, n (%)

3 (33.3)

3 (30.0)

> 0.99

 DGF duration (days)

7.33 ± 5.68

19.66 ± 0.57

0.02

 eGFRb at discharge (ml/min/1.73m2)

55.80 ± 21.14

52.02 ± 11.71

0.63

 eGFR 1 month after transplantation (ml/min/1.73m2)

52.0 (18.9-84.4)

47.2 (36.0-85.5)

0.71

 eGFR 2 months after transplantation (ml/min/1.73m2)

46.05 ± 16.2

60.6 ± 16.6

0.08

 eGFR 3 months after transplantation (ml/min/1.73m2)

55.75 ± 18.23

60.01 ± 16.49

0.30

 SCrc at discharge (mg/dL)

1.3 (1.1-3)

1.4 (1-2.1)

0.56

 SCr 1 month after transplantation (mg/dL)

1.6 (1.0-2.9)

1.3 (0.8-1.9)

0.34

 SCr 2 months after transplantation (mg/dL)

1.7 (1.2-2.8)

1.22 (0.8-1.6)

0.009

 SCr 3 months after transplantation (mg/dL)

1.40 (1.1-3.08)

1.13 (0.9-2)

0.07

Secondary

 Hospitalization duration (days)

14 (9-48)

18 (8-32)

0.87

 Total acute rejection, n (%)

6 (66.6)

4 (40.0)

0.37

 AMRd, n (%)

2 (22.2)

2 (20.0)

> 0.99

 TCMRe, n (%)

2 (22.2)

2 (20.0)

> 0.99

 Mixed rejection episode, n (%)

2 (22.2)

0

0.21

 Time to first rejection (days)

10 (5-72)

11.5 (5-18)

0.78

  1. Data have been presented as mean ± SD, median (minimum-maximum), or the number of patients (%) as indicated
  2. aDGF delayed graft function
  3. beGFR estimated glomerular filtration rate
  4. cSCr serum creatinine concentration
  5. dAMR antibody-mediated rejection
  6. eTCMR T cell-mediated rejection